Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenelzine plus Docetaxel in CRPC
NCT01253642Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jul 2010
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of phenelzine in castration-resistant prostate cancer (CRPC), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Proportion of Patients Who Experience a PSA Decline of at Least 30% at 12 weeks. Started Jul 2010; status: terminated.
02
Drugs
phenelzine
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01253642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01253642.